NL930095I2 - Aromatische heterocyclische esters van steroiden, de bereiding daarvan en farmaceutische composities, die deze verbindingen bevatten. - Google Patents

Aromatische heterocyclische esters van steroiden, de bereiding daarvan en farmaceutische composities, die deze verbindingen bevatten.

Info

Publication number
NL930095I2
NL930095I2 NL930095C NL930095C NL930095I2 NL 930095 I2 NL930095 I2 NL 930095I2 NL 930095 C NL930095 C NL 930095C NL 930095 C NL930095 C NL 930095C NL 930095 I2 NL930095 I2 NL 930095I2
Authority
NL
Netherlands
Prior art keywords
aromatic heterocyclic
steroids
compounds
preparation
pharmaceutical compositions
Prior art date
Application number
NL930095C
Other languages
English (en)
Dutch (nl)
Other versions
NL930095I1 (nl
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NL930095I1 publication Critical patent/NL930095I1/nl
Publication of NL930095I2 publication Critical patent/NL930095I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J33/00Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NL930095C 1981-02-02 1993-06-24 Aromatische heterocyclische esters van steroiden, de bereiding daarvan en farmaceutische composities, die deze verbindingen bevatten. NL930095I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23076381A 1981-02-02 1981-02-02

Publications (2)

Publication Number Publication Date
NL930095I1 NL930095I1 (nl) 1993-10-01
NL930095I2 true NL930095I2 (nl) 1994-12-01

Family

ID=22866476

Family Applications (1)

Application Number Title Priority Date Filing Date
NL930095C NL930095I2 (nl) 1981-02-02 1993-06-24 Aromatische heterocyclische esters van steroiden, de bereiding daarvan en farmaceutische composities, die deze verbindingen bevatten.

Country Status (25)

Country Link
US (1) US4472393A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0057401B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS57146800A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890000761B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE8790T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU549102B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG60799B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1177822A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1359A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3260474D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK162770C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI78111C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK68487A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU188769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE52576B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL64885A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KE (1) KE3694A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203403A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL930095I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO157020C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ199600A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA07116A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH19733A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT74357B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA82566B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446177A (en) * 1984-12-28 1995-08-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4914090A (en) * 1985-11-01 1990-04-03 Schering Corporation Ophthalmic compositions
IL79661A (en) * 1986-08-08 1991-01-31 Yeda Res & Dev Antiviral composition containing hypericin or pseudohypericin
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
YU48707B (sh) * 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
IL99437A (en) 1990-09-10 1995-05-29 Schering Corp Mometasone furoate monohydrate process for making same and pharmaceutical compositions
DK0588897T3 (da) 1991-06-10 1996-03-18 Schering Corp Aerosolformuleringer, der i det væsentlige er fri for chlorfluorcarbonforbindelser
ZA924163B (en) 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
TW442281B (en) * 1993-12-21 2001-06-23 Schering Corp Pharmaceutical compositions for treating psoriasis and other hyperkeratotic and/or scaly dermatoses
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
DE4433374A1 (de) * 1994-09-20 1996-03-21 Hoechst Ag 17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
DE69709655T2 (de) * 1996-06-28 2002-09-12 Schering Corp., Kenilworth Verfahren zur herstellung von 17-estern von 9alpha,21-dihalopregan-11beta,17alpha-diol-20-onen
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6297227B1 (en) 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
NZ500555A (en) * 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
PT102405A (pt) * 2000-01-20 2001-07-31 Hovione Farmaciencia Sa Processo para a preparacao de mometasona
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
JP4446661B2 (ja) * 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体
JP2005500290A (ja) * 2001-06-12 2005-01-06 グラクソ グループ リミテッド 抗炎症性の、17β−カルボチオアートアンドロスタン誘導体である17α複素環エステル
GB0125259D0 (en) * 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
GB0127160D0 (en) * 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) * 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Iv型ホスホジエステラーゼの阻害剤
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
DE602005020113D1 (de) 2004-01-21 2010-05-06 Schering Corp Verfahren zur behandlung von akuten rhinosinusitis
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20090325917A1 (en) * 2006-10-19 2009-12-31 Cipla Limited Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2120868A4 (en) * 2007-04-11 2010-08-25 Perrigo Israel Phamaceuticals LOW-DOSED MOMETASON FORMULATIONS
WO2009063493A2 (en) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
US20090082318A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched mometasone
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
NZ603107A (en) 2008-05-28 2014-03-28 Validus Biopharma Inc Non-hormonal steroid modulators of nf-kb for treatment of disease
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
KR101926060B1 (ko) * 2009-05-29 2018-12-06 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
ES2683864T3 (es) 2009-10-01 2018-09-28 Adare Pharmaceuticals, Inc. Composiciones de corticosteroides administradas oralmente
WO2011093810A2 (en) 2010-01-28 2011-08-04 Bilgic Mahmut Dry powder pharmaceutical composition comprising tiotropium and mometasone
EP2533765A2 (en) 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013109207A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising mometasone
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
RU2698331C2 (ru) 2013-03-14 2019-08-26 Новартис Аг Деаморфизация высушенных распылением составов посредством смешивания распылением
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
CA2912927A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
AU2015237857B2 (en) 2014-03-27 2017-08-10 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
CN105481933B (zh) * 2015-12-25 2017-09-19 山东京卫制药有限公司 一种合成糠酸莫米松的方法
CN107266519B (zh) * 2016-04-08 2021-06-29 天津金耀集团有限公司 一种9β,11β-环氧-17α-羟基-16α-甲基-21-氯代-1,4孕甾二烯-3,20-二酮新晶型及其制备方法
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN107793462A (zh) * 2016-08-30 2018-03-13 天津太平洋制药有限公司 一种丙酸氯倍他索的制备方法
CN107778341A (zh) * 2016-08-30 2018-03-09 天津太平洋制药有限公司 一种哈西奈德的制备方法
CN109206466B (zh) * 2017-06-30 2022-08-09 天津药业研究院股份有限公司 一种甾体21位羟基氯代或溴代方法
CN109206468B (zh) * 2017-06-30 2023-06-27 天津药业研究院股份有限公司 一种糠酸莫米松的制备方法
CN107573398B (zh) * 2017-09-07 2021-02-26 山东泰华生物科技股份有限公司 一种哈西奈德及其衍生物的制备方法
CN108395465B (zh) * 2018-05-10 2019-07-30 浙江仙居仙乐药业有限公司 一种地塞米松环氧水解物的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
EP4566595A1 (en) 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059906B (de) * 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3557158A (en) * 1962-01-22 1971-01-19 Upjohn Co 6alpha-fluoro-16-methyl - 4 - pregnene 3,20-diones and intermediates produced in the synthesis thereof
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
IT1061787B (it) * 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) * 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
GB1505701A (en) * 1975-06-14 1978-03-30 Pierrel Spa 2-chloro-6beta-fluoropregnanes
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids

Also Published As

Publication number Publication date
NO157020B (no) 1987-09-28
ATE8790T1 (de) 1984-08-15
JPS6360036B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-11-22
PH19733A (en) 1986-06-17
IE52576B1 (en) 1987-12-23
EP0057401B1 (en) 1984-08-01
IL64885A0 (en) 1982-03-31
IE820207L (en) 1982-08-02
JPS57146800A (en) 1982-09-10
NZ199600A (en) 1984-09-28
ZA82566B (en) 1982-12-29
DK162770B (da) 1991-12-09
AU549102B2 (en) 1986-01-16
HK68487A (en) 1987-10-02
FI78111C (fi) 1989-06-12
NO820263L (no) 1982-08-03
NO157020C (no) 1988-01-06
AU7991882A (en) 1982-08-12
IL64885A (en) 1985-05-31
BG60799B2 (bg) 1996-03-29
EP0057401A1 (en) 1982-08-11
PT74357A (en) 1982-02-01
FI78111B (fi) 1989-02-28
NL930095I1 (nl) 1993-10-01
OA07116A (fr) 1984-03-31
KR830009138A (ko) 1983-12-17
FI820280L (fi) 1982-08-03
PT74357B (en) 1984-05-30
DE3260474D1 (en) 1984-09-06
MX9203403A (es) 1992-07-01
US4472393A (en) 1984-09-18
HU188769B (en) 1986-05-28
DK162770C (da) 1992-04-27
DK39082A (da) 1982-08-03
KE3694A (en) 1987-03-13
KR890000761B1 (ko) 1989-04-05
CY1359A (en) 1987-08-07
CA1177822A (en) 1984-11-13
NO1994018I1 (no) 1994-10-07

Similar Documents

Publication Publication Date Title
NL930095I1 (nl) Aromatische heterocyclische esters van steroïden de bereiding daarvan en farmaceutische composities die deze verbindingen bevatten
DE3369508D1 (en) Triphenylimidazolyloxyalcanoic acids and their derivatives, process for their preparation and pharmaceutical compositions containing them
HK87285A (en) Mercapto-imidazole derivatives,their preparation,mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
FI891986A7 (fi) Farmaseuttiset koostumukset psoriasiksen hoitoon
DE3261760D1 (en) Pharmaceutical compositions for the treatment of skin
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
GB2022998B (en) Phermaceutical composition for the treatment of neoplasticand other diseases
IT1210935B (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
DE3162277D1 (en) N-(4-phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound
IT7922548A0 (it) Derivati del 1,5-dimetilbiciclo(3.2.1.)-ottano, preparazione di questi composti eloro impiego come composti per profumi.
RO86562A2 (ro) Compozitie vegetala medicamentoasa pentru tratarea unor afectiuni hepato-biliare
BE892781A (fr) Nouvelles compositions pharmaceutiques pour le traitement du diabete
RO77124A2 (ro) Compozitie medicamentoasa destinata tratamentului aftelor bucale
IL82376A (en) Pharmaceutical composition for the treatment of inflammatory conditions
ZA80619B (en) New laevorotatory basic derivative of 9,10-ethanoanthracene,process for the manufacture thereof,pharmaceutical compositions containing this compound and their use
IL89472A0 (en) Pharmaceutical compositions containing sufotidine for the treatment of inflammatory conditions
IT1111319B (it) Serie di elementi per la composizione di mobili